Axiom Investors LLC DE Takes Position in Axon Enterprise, Inc $AXON

Axiom Investors LLC DE acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 176,991 shares of the biotechnology company’s stock, valued at approximately $93,088,000. Axiom Investors LLC DE owned 0.23% of Axon Enterprise as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Napa Wealth Management boosted its stake in shares of Axon Enterprise by 26.3% in the first quarter. Napa Wealth Management now owns 567 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 118 shares during the period. Jump Financial LLC boosted its stake in shares of Axon Enterprise by 8.6% in the first quarter. Jump Financial LLC now owns 39,797 shares of the biotechnology company’s stock valued at $20,931,000 after purchasing an additional 3,151 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Axon Enterprise by 5.0% during the first quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock worth $203,000 after buying an additional 18 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in shares of Axon Enterprise by 0.8% during the first quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 13,853 shares of the biotechnology company’s stock worth $7,286,000 after buying an additional 104 shares in the last quarter. Finally, AlphaQuest LLC grew its position in shares of Axon Enterprise by 15.2% during the first quarter. AlphaQuest LLC now owns 1,003 shares of the biotechnology company’s stock worth $528,000 after buying an additional 132 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 0.2%

AXON stock opened at $728.41 on Monday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a twelve month low of $346.71 and a twelve month high of $885.91. The company’s 50 day moving average is $765.93 and its two-hundred day moving average is $680.55. The stock has a market cap of $57.18 billion, a P/E ratio of 179.85, a PEG ratio of 26.73 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $668.54 million for the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter last year, the company earned $1.20 earnings per share. The firm’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $831.29, for a total value of $8,312,900.00. Following the completion of the sale, the chief executive officer owned 3,053,982 shares in the company, valued at approximately $2,538,744,696.78. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the sale, the president owned 238,379 shares of the company’s stock, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,865 shares of company stock valued at $26,926,433 in the last 90 days. Company insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AXON shares. The Goldman Sachs Group boosted their price objective on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th. Northland Securities set a $800.00 price objective on Axon Enterprise in a research report on Tuesday, August 5th. Wolfe Research started coverage on Axon Enterprise in a research report on Monday, July 7th. They set an “outperform” rating for the company. Raymond James Financial reissued an “outperform” rating and set a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, JMP Securities boosted their price objective on Axon Enterprise from $725.00 to $825.00 and gave the stock a “market outperform” rating in a research report on Tuesday, July 22nd. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $837.69.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.